Formulation development and evaluation of Glibenclamide loaded Eudragit RLPO microparticles

Authors

  • Balagani Pavan Kumar Assistant Professor Department of Pharmaceutics Gokula Krishna College of Pharmacy Sullurpet-524121, A.P
  • Irisappan Sarath Chandiran Professor & Principal Department of Pharmaceutics, Gokula Krishna College of Pharmacy Sullurpet-524121, A.P
  • Korlakunta Narasimha Jayaveera Director International Science-Tech Research Institute Anantapur ? 515 001, A.P

DOI:

https://doi.org/10.3329/icpj.v2i12.17016

Keywords:

Microencapsulation, controlled release, diabetes mellitus, sulphonyl ureas, in vitro evaluation, release kinetics

Abstract

The objective of the present investigation was to formulate and evaluate microencapsulated Glibenclamide produced by the emulsion solvent evaporation method. Microparticles were prepared using Eudragit RLPO by emulsion solvent evaporation method and characterized for their micromeritic properties, encapsulation efficiency, particle size, drug loading, FTIR, DSC, SEM analysis. In vitro release studies were performed in phosphate buffer (pH 7.4). Stability studies were conducted as per ICH guidelines. The resulting microparticles obtained by solvent evaporation method were free flowing in nature. The mean particle size of microparticles ranges from 134.49 179.72 µm and encapsulation efficiency ranges from 92.30-98.32%. The infrared spectra and differential scanning calorimetry thermographs confirmed the stable character of Glibenclamide in the drug-loaded microparticles. Scanning electron microscopy revealed that the microparticles were spherical in nature. In vitro release studies revealed that the drug release was sustained up to 12 hrs. The release kinetics of Glibenclamide from optimized formulation followed zero-order and peppas mechanism. The mechanism of drug release from the microparticles was found to be non-Fickian type. Eudragit RLPO microparticles containing Glibenclamide could be prepared successfully by using an emulsion solvent evaporation technique, which will not only sustain the release of drug but also manage complicacy of the diabetes in a better manner.

DOI: http://dx.doi.org/10.3329/icpj.v2i12.17016

International Current Pharmaceutical Journal, November 2013, 2(12): 196-201

Downloads

Download data is not yet available.
Abstract
869
PDF
1269

Downloads

Published

2013-11-14

How to Cite

Kumar, B. P., Chandiran, I. S., & Jayaveera, K. N. (2013). Formulation development and evaluation of Glibenclamide loaded Eudragit RLPO microparticles. International Current Pharmaceutical Journal, 2(12), 196–201. https://doi.org/10.3329/icpj.v2i12.17016

Issue

Vol. 2 No. 12 (2013)

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

  1. The journal holds copyright and publishes the work under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).